Hims & Hers (HIMS) Stock Jumps 45% — Can This Momentum Continue?
The post Hims & Hers (HIMS) Stock Jumps 45% — Can This Momentum Continue? appeared on BitcoinEthereumNews.com. Key Takeaways Bank of America increased HIMS price target to $37 (up from $36) while maintaining Neutral rating due to valuation worries Monthly oral Wegovy subscriber additions stalled in June according to credit card transaction data HIMS shares have surged more than 45% over the last month following Eucalyptus purchase and international growth strategy More than 28% of the free float remains short, indicating continued market doubt Analyst consensus leans Moderate Buy, though mean price target at $30.14 suggests approximately 16% downside potential Hims & Hers Health (HIMS) currently trades at $36.07, reflecting a remarkable 45%+ gain over the past month. However, Bank of America Securities recently bumped its price objective to $37 from $36 while sticking with a Neutral stance — a modest adjustment that speaks volumes about Wall Street’s hesitation. Hims & Hers Health, Inc